Gilenya fingolimod: Phase III data

The double-blind, international Phase III INFORMS trial in 970 patients ages 25-69 with PPMS

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE